{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-21-015281","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2021-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.068457+00:00","generated_at":"2026-06-28T10:31:44.292057+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Altimmune Q3 net loss $33.5M; pemvidutide shows liver fat reduction to undetectable levels","bullets":["Net loss of $33.5M ($0.81 per share) for Q3 2021, up from $17.8M in Q3 2020.","Cash and short-term investments totaled $199.9M at Sept 30, 2021; revenue fell to $0.2M from $2.9M.","Phase 1 pemvidutide data: mean weight loss up to 10.3% at 1.8 mg at week 12 without dose titration.","MRI-PDFF analysis in 5 subjects with hepatic steatosis showed liver fat fell to undetectable levels within 6 weeks (≥90% reduction).","Phase 2 obesity and NASH trials expected to start in 2022; IND for obesity by year-end 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-21-015281","json":"https://secwatch.observer/filing/0001558370-21-015281.json","markdown":"https://secwatch.observer/filing/0001558370-21-015281.md","text":"https://secwatch.observer/filing/0001558370-21-015281.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000155837021015281/0001558370-21-015281-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000155837021015281/alt-20211109x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T10:31:44.292057+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}